Tipifarnib, a farnesyl transferase inhibitor, appears to have potential for patients with locally advanced breast cancer

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tipifarnib promising in advanced breast cancer

Inpharma, Vol. 1, Iss. 1402, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Farnesyl transferase inhibitors in the treatment of breast cancer

By Kelland Lloyd R

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 413-421

Informa Healthcare

Access to resources Recommend Favorite

Heteronemin as a Protein Farnesyl Transferase Inhibitor

By Ledroit Véronique Debitus Cécile Ausseil Frédéric Raux Roselyne Menou Jean-Louis Hill Bridget

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 42, Iss. 6, 2004-09 ,pp. : 454-456

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study

By Macdonald John McCoy Sheryl Whitehead Robert Iqbal Syma Wade James Giguere Jeffrey Abbruzzese James

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 485-487

Springer Publishing Company

Access to resources Recommend Favorite

Sorafenib in locally advanced or metastatic breast cancer

By Gradishar William J

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 8, 2012-08 ,pp. : 1177-1191

Informa Healthcare

Access to resources Recommend Favorite